2025

Tecovirimat news continues: Japan approval includes mpox indication

2 January 2025. Related: Early access, mpox (monkeypox).

Looking back through 2024 and forward to 2025…

1 January 2025. Related: Early access, Special reports.

i-Base appeal: Q&A services and the website in 2025

1 January 2025. Related: Editorial, Special reports.

Future meetings and webinars 2025

1 January 2025. Related: Future meetings.

ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir

1 January 2025. Related: Conference reports, Pipeline report, Antiretrovirals.

Transient impact of lenacapavir against MDR HIV-2 without other active ART

1 January 2025. Related: Early access, Antiretrovirals, Treatment strategies, Virology, Drug resistance.

Lenacapavir submitted to the US FDA with an indication for HIV PrEP

1 January 2025. Related: Early access, Antiretrovirals, Treatment access, HIV prevention and transmission.